Allotera Therapeutics
PrivateLast Round
Series C
Extension
Jul 8, 2026
Total Funding Raised
$394M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Allotera Therapeutics is a biotechnology company developing allogeneic, off-the-shelf CAR-T cell therapies for the treatment of hematological malignancies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allotera Therapeutics Comparables
Compare Allotera Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Bioheng Therapeutics | 89% | |
| Beam Therapeutics | 83% | |
| AvenCell | 81% |
Allotera Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C Extension | Jul 8, 2026 | ||||
| Series C | Aug 27, 2025 | ||||
| Series B | Jul 15, 2021 | ||||
| Series A | Apr 13, 2020 |
Key People
Founding team and executive leadership
Allotera Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| LYZZ Capital | Series B, Series C, Series A |
| Intermediate Capital Group | Series C, Series B |
| Fidelity Management & Research Company | Series B, Series C |
| BioGenerator Ventures | Series C Extension, Series A |
| Tybourne Capital Management | Series C, Series B |
| RiverVest Venture Partners | Series B, Series C, Series A |
| Abingworth | Series C, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 8, 2026
$35M round with participation from BioGenerator Ventures and LightChain Capital.
- Aug 27, 2025
$115M raised in early funding.
Allotera Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Allotera Therapeutics's valuation, stock price, and market status.
Is Wugen a public or private company?
Wugen is a private company.
What is the current stock price of Wugen?
Wugen is a private company with no public stock price. No recent secondary market data is available.
How much is Wugen worth (valuation)?
Valuation information for Wugen is not publicly available.
Can I buy Wugen stock?
Wugen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Wugen's last funding round?
Wugen's most recent funding round was Early Funding on August 27, 2025.
Who are the main investors in Wugen?
Key investors in Wugen include Fidelity Management & Research Company, Tybourne Capital Management, RiverVest Venture Partners, Abingworth.
Will Wugen IPO soon?
No public IPO plans have been announced for Wugen.
How can I track Wugen secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Wugen's secondary market activity and sign up for updates.